Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Roivant Sciences Ltd.ROIV · Entity 3185 | CFO | September 20, 2026 | September 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Roivant Sciences Ltd.
Report date September 20, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 269,681 |
Reported balance
After 2026-09-20 transaction · row 1
1 source rowRow 1 · 2026-09-20 · Tax withholding · Disposed 2,129 · Balance 269,681 F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 30, 2023 Filed Nov 2, 2023 01:39 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 2,360 | $8.39 | $19,800.40 |
DisclosureSEC source: 0001140361-23-050941 · form4.xml · nonDerivative · entry 1 Pulik Richard · CIK 0001885841 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 277,352 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. Read SEC document |
| September 29, 2023 Filed Oct 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 2,483 | $11.86 | $29,448.38 |
DisclosureSEC source: 0001140361-23-046751 · form4.xml · nonDerivative · entry 1 Pulik Richard · CIK 0001885841 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,712 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. Read SEC document |
| August 29, 2023 Filed Sep 1, 2023 10:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 2,368 | $11.19 | $26,497.92 |
DisclosureSEC source: 0001140361-23-042154 · form4.xml · nonDerivative · entry 1 Pulik Richard · CIK 0001885841 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,195 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. Read SEC document |
| August 01, 2023 Filed Aug 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 2,306 | $11.86 | $27,349.16 |
DisclosureSEC source: 0001140361-23-037943 · form4.xml · nonDerivative · entry 1 Pulik Richard · CIK 0001885841 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,563 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · balance_after: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan. Read SEC document |
| June 29, 2023 Filed Jul 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,667 | $10.11 | $16,853.37 |
DisclosureSEC source: 0001140361-23-032892 · form4.xml · nonDerivative · entry 1 Pulik Richard · CIK 0001885841 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,373 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,711 | $9.08 | $15,535.88 |
DisclosureSEC source: 0001140361-23-028195 · form4.xml · nonDerivative · entry 1 Pulik Richard · CIK 0001885841 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,040 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. Read SEC document |
| May 01, 2023 Filed May 4, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,667 | $8.61 | $14,352.87 |
DisclosureSEC source: 0001140361-23-022810 · form4.xml · nonDerivative · entry 1 Pulik Richard · CIK 0001885841 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,751 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. Read SEC document |
| April 20, 2023 Filed Apr 25, 2023 01:28 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 383,496 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001140361-23-019991 · form4.xml · derivative · entry 2 Pulik Richard · CIK 0001885841 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 383,496 Underlying: Common Shares · 383,496 shares Expires 2033-04-19 F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2023. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date. Read SEC document |
| April 20, 2023 Filed Apr 25, 2023 01:28 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 66,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-019991 · form4.xml · nonDerivative · entry 1 Pulik Richard · CIK 0001885841 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,418 F1 · shares: Reflects an award of 66,710 restricted stock units with respect to Common Shares ("RSUs") with a vesting commencement date of April 20, 2023. 1/4 of the RSUs service-vest twelve (12) months after the vesting commencement date; 1/16 of the RSUs service-vest fourteen (14) months after the vesting commencement date; and the balance of the RSUs service-vest in a series of eleven (11) successive equal quarterly installments measured from the date fourteen (14) months after the vesting commencement date, subject to the reporting person's Continuous Service through the applicable vesting date. Read SEC document |
| March 29, 2023 Filed Apr 1, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,639 | $7.35 | $12,046.65 |
DisclosureSEC source: 0001140361-23-015526 · form4.xml · nonDerivative · entry 1 Pulik Richard · CIK 0001885841 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,708 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 1,912 | $8.08 | $15,448.96 |
DisclosureSEC source: 0001140361-23-010166 · form4.xml · nonDerivative · entry 1 Pulik Richard · CIK 0001885841 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,347 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · balance_after: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan. Read SEC document |
| April 20, 2022 Filed Apr 22, 2022 23:26 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0000899243-22-015519 · doc4.xml · derivative · entry 1 Pulik Richard · CIK 0001885841 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Shares · 1,000,000 shares Expires 2032-04-19 F1 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 20:07 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 313,419 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0000950103-21-016280 · dp160198_4-pulik.xml · derivative · entry 1 Pulik Richard · CIK 0001885841 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,419 Underlying: Common Shares · 313,419 shares Expires 2031-10-19 F1 · derivative.exercise_date: Represents an award of stock options ("Options") to purchase Common Shares with a vesting commencement date of September 28, 2021. Award of Options vests and becomes exercisable as follows: (i) 25% on the one-year anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.